Company Shouyao Holdings (Beijing) Co., LTD.

688197

CNE1000062V6

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
45.6 ^CNY	+4.56%		+4.11%	-17.38%

28/04	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/03	1,859,000 A Shares of Shouyao Holdings Co., LTD. are subject to a Lock-Up Agreement Ending on 23-MAR-2024.	CI

Shouyao Holdings Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main business is the research and development of small molecule innovative drugs in the clinical stage. The Company's main products include anaplastic lymphoma kinase (ALK) kinase inhibitors, selective inhibitors and others. The Company's pharmaceutical products are used in key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as disease areas such as type II diabetes. The Company mainly operates in the domestic market.

Number of employees: 185

CNY in Million	2022	Weight	2023	Weight	Delta
Technology Development and Services 100.0 %	2	100.0 %	5	100.0 %	+186.18%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	2	100.0 %	5	100.0 %	+186.18%

Managers	Title	Age	Since
Wen Jun Li CEO	Chief Executive Officer	57	01/16/01
Ya Jie Wang DFI	Director of Finance/CFO	54	01/17/01
Ying Hui Sun CTO	Chief Tech/Sci/R&D Officer	44	01/10/01
Xi Chen BRD	Director/Board Member	34	01/19/01
Ying Li Zhang IRC	Investor Relations Contact	40	01/16/01
Jing Can Wang PRN	Corporate Officer/Principal	41	01/21/01
Xi Jie Liu PRN	Corporate Officer/Principal	48	01/16/01

Members of the board	Title	Age	Since
Xue Liu BRD	Director/Board Member	62	04/21/04
Ting Li BRD	Director/Board Member	35	01/21/01
Wen Jun Li CEO	Chief Executive Officer	57	01/16/01
Xin He Xu BRD	Director/Board Member	50	01/19/01
Jing Han Wang BRD	Director/Board Member	35	01/20/01
Shuang Liu BRD	Director/Board Member	35	27/20/27
Xi Chen BRD	Director/Board Member	34	01/19/01
Ya Jie Wang DFI	Director of Finance/CFO	54	01/17/01
Ying Li Zhang IRC	Investor Relations Contact	40	01/16/01
Xi Jie Liu PRN	Corporate Officer/Principal	48	01/16/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	148,719,343	35,017,914 ( 23.55 %)	0	23.55 %

Name	Equities	%	Valuation
Beijing E-Town International Investment & Development Co., Ltd 13.42 %	7,289,480	13.42 %	45 M ¥
Penghua Fund Management Co., Ltd. 12.42 %	6,745,778	12.42 %	42 M ¥
BEIJING SL PHARMACEUTICAL CO., LTD. 11.72 %	6,364,279	11.72 %	39 M ¥
China Fund Management Co., Ltd. 4.357 %	2,366,090	4.357 %	15 M ¥
Hwabao WP Fund Management Co., Ltd. 2.683 %	1,457,036	2.683 %	9 M ¥
Bank of China Investment Management Co., Ltd. 2.285 %	1,240,903	2.285 %	8 M ¥
GF Fund Management Co., Ltd. 2.119 %	1,151,062	2.119 %	7 M ¥
Shenzhen Julin Investment Management Co. Ltd. 1.825 %	990,971	1.825 %	6 M ¥
Bosera Asset Management Co., Ltd. 1.558 %	846,339	1.558 %	5 M ¥
Huagai Capital Co. Ltd. 1.216 %	660,648	1.216 %	4 M ¥

Shouyao Holdings (Beijing) Co. Ltd.

Building 15, Yuquan Huigu No. 3 Minzhuang Road

100195, Beijing

http://www.shouyaoholding.com

address Shouyao Holdings (Beijing) Co., LTD.(688197)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.6 CNY

Average target price

67 CNY

Spread / Average Target

+46.93%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
SHOUYAO HOLDINGS (BEIJING) CO., LTD.	-17.38%	893M
ELI LILLY AND COMPANY	+54.61%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+20.62%	337B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.61%	171B

Other Pharmaceuticals